

METFORMIN HYDROCHLORIDE - metformin hydrochloride tablet, extended release

Aurobindo Pharma Limited

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.

METFORMIN HYDROCHLORIDE extended-release tablets, for oral use
Initial U.S. Approval: 1995

WARNING: LACTIC ACIDOSIS

See full prescribing information for complete boxed warning.

- **Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. (5.1)**
- **Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. (5.1)**
- **If lactic acidosis is suspected, discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)**

INDICATIONS AND USAGE

Metformin hydrochloride is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1)

DOSAGE AND ADMINISTRATION

- Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew (2.1)
- Starting dose: 500 mg orally once daily with the evening meal (2.1)
- Increase the dose in increments of 500 mg weekly, up to a maximum of 2,000 mg once daily with the evening meal (2.1)
- Patients receiving metformin hydrochloride (HCl) tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily (2.1)

Renal Impairment:

- Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.2)
 - Do not use in patients with eGFR below 30 mL/minute/1.73 m² (2.2)
 - Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m² (2.2)
 - Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m² (2.2)
 - Discontinue if eGFR falls below 30 mL/minute/1.73 m² (2.2)

Discontinuation for Iodinated Contrast Imaging Procedures:

- Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.3)

DOSAGE FORMS AND STRENGTHS

Extended-Release Tablets: 500 mg and 1,000 mg (3)

CONTRAINDICATIONS

- Severe renal impairment (eGFR below 30 mL/min/1.73 m²) (4, 5.1)
- Hypersensitivity to metformin (4)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. (4)

-----**WARNINGS AND PRECAUTIONS**-----

- *Lactic Acidosis*: See boxed warning. (5.1)
- *Vitamin B₁₂ Deficiency*: Metformin may lower vitamin B₁₂ levels. Measure hematological parameters annually and vitamin B₁₂ at 2 to 3 year intervals and manage any abnormalities. (5.2)
- *Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues*: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required. (5.3)

-----**ADVERSE REACTIONS**-----

Common adverse reactions are diarrhea, nausea/vomiting, abdominal pain, constipation, abdomen distention, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----**DRUG INTERACTIONS**-----

- Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring (7)
- Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use (7)
- Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake (7)

-----**USE IN SPECIFIC POPULATIONS**-----

- **Females and Males of Reproductive Potential**: Advise premenopausal females of the potential for an unintended pregnancy. (8.3)
- **Geriatric Use**: Assess renal function more frequently. (8.5)
- **Hepatic Impairment**: Avoid use in patients with hepatic impairment. (8.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 4/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: LACTIC ACIDOSIS

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Adult Dosage and Administration

2.2 Recommendations for Use in Renal Impairment

2.3 Discontinuation for Iodinated Contrast Imaging Procedures

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Lactic Acidosis

5.2 Vitamin B₁₂ Deficiency

5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues

5.4 Macrovascular Outcomes

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: LACTIC ACIDOSIS

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see *Warnings and Precautions (5.1)*].

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see *Warnings and Precautions (5.1)*].

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see *Dosage and Administration (2.2)*, *Contraindications (4)*, *Warnings and Precautions (5.1)*].

If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see *Warnings and Precautions (5.1)*].

1 INDICATIONS AND USAGE

Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

2 DOSAGE AND ADMINISTRATION

2.1 Adult Dosage and Administration

- Swallow metformin hydrochloride extended-release tablet whole and never crush, cut or chew.
- The recommended starting dose of metformin hydrochloride extended-release tablet is 500 mg orally once daily with the evening meal.
- Increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal.
- If glycemic control is not achieved with metformin hydrochloride extended-release tablets 2,000 mg once daily, consider a trial of metformin hydrochloride extended-release tablets 1,000 mg twice daily.

- Patients receiving metformin hydrochloride (HCl) may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily.

2.2 Recommendations for Use in Renal Impairment

- Assess renal function prior to initiation of metformin hydrochloride extended-release tablets and periodically thereafter.
- Metformin hydrochloride extended-release tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m².
- Initiation of metformin hydrochloride extended-release tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m² is not recommended.
- In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/min/1.73 m², assess the benefit risk of continuing therapy.
- Discontinue metformin hydrochloride extended-release tablets if the patient's eGFR later falls below 30 mL/minute/1.73 m² [see *Contraindications (4) and Warnings and Precautions (5.1)*].

2.3 Discontinuation for Iodinated Contrast Imaging Procedures

Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable.

3 DOSAGE FORMS AND STRENGTHS

Metformin hydrochloride extended-release tablets are available as:

- *Extended-release tablets*: 500 mg white to off-white round biconvex tablets imprinted with 'MTN 500' on one side with black ink.
- *Extended-release tablets*: 1,000 mg white to off-white round biconvex tablets imprinted with 'MTN 1000' on one side with black ink.

4 CONTRAINDICATIONS

Metformin hydrochloride extended-release tablets are contraindicated in patients with:

- Severe renal impairment (eGFR below 30 mL/min/1.73 m²) [see *Warnings and Precautions (5.1)*].
- Hypersensitivity to metformin.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.

5 WARNINGS AND PRECAUTIONS

5.1 Lactic Acidosis

There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels were generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.

If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of metformin hydrochloride extended-release tablets. In metformin hydrochloride extended-release tablets treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.

Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue metformin hydrochloride extended-release tablets and report these symptoms to their healthcare provider.

For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:

- *Renal impairment*—The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment.

The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient's renal function include [see *Dosage and Administration (2.2)*, *Clinical Pharmacology (12.3)*]:

- Before initiating metformin hydrochloride extended-release tablets, obtain an estimated glomerular filtration rate (eGFR).
- Metformin hydrochloride extended-release tablets are contraindicated in patients with an eGFR less than 30 mL/min/1.73 m² [see *Contraindications (4)*].
- Initiation of metformin hydrochloride extended-release tablets are not recommended in patients with eGFR between 30 to 45 mL/min/1.73 m².
- Obtain an eGFR at least annually in all patients taking metformin hydrochloride extended-release tablets. In patients at risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently.
- In patients taking metformin hydrochloride extended-release tablets whose eGFR falls below 45 mL/min/1.73 m², assess the benefit and risk of continuing therapy.
- *Drug interactions* — The concomitant use of metformin hydrochloride extended-release tablets with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation [see *Drug Interactions (7)*]. Consider more frequent monitoring of patients.

- *Age 65 or greater* — The risk of metformin-associated lactic acidosis increases with the patient's age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients.
- *Radiologic studies with contrast* — Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart metformin hydrochloride extended-release tablets if renal function is stable.
- *Surgery and other procedures* — Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension, and renal impairment. Metformin hydrochloride extended-release tablets should be temporarily discontinued while patients have restricted food and fluid intake.
- *Hypoxic states* — Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may cause prerenal azotemia. When such an event occurs, discontinue metformin hydrochloride extended-release tablets.
- *Excessive alcohol intake* — Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets.
- *Hepatic impairment* — Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of metformin hydrochloride extended-release tablets in patients with clinical or laboratory evidence of hepatic disease.

Mitochondrial Diseases: Metformin may increase the risk of lactic acidosis in patients with mitochondrial diseases such as mitochondrial encephalopathy with lactic acidosis, and stroke-like episodes (MELAS) syndrome and maternally inherited diabetes and deafness (MIDD). Metformin hydrochloride extended-release tablets are not recommended in patients with mitochondrial diseases.

If a patient taking metformin hydrochloride extended-release tablet develops elevated lactic acid levels (with or without accompanying neurologic signs and symptoms), discontinue metformin hydrochloride extended-release tablets. Depending on the clinical context, consider evaluating the patient for MELAS, MIDD, or other mitochondrial disease.

5.2 Vitamin B₁₂ Deficiency

In clinical trials of 29-week duration with metformin hydrochloride tablets, a decrease to subnormal levels of previously normal serum vitamin B₁₂ levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B₁₂ absorption from the B₁₂-intrinsic factor complex, may be associated with anemia but

appears to be rapidly reversible with discontinuation of metformin or vitamin B₁₂ supplementation. Certain individuals (those with inadequate vitamin B₁₂ or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B₁₂ levels. Measure hematologic parameters on an annual basis and vitamin B₁₂ at 2 to 3 year intervals in patients on metformin hydrochloride extended-release tablets and manage any abnormalities [see *Adverse Reactions (6.1)*].

5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues

Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Metformin hydrochloride extended-release tablets may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with metformin hydrochloride extended-release tablets [see *Drug Interactions (7)*].

5.4 Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin hydrochloride extended-release tablets.

6 ADVERSE REACTIONS

The following adverse reactions are also discussed elsewhere in the labeling:

- Lactic Acidosis [see *Boxed Warning and Warnings and Precautions (5.1)*]
- Vitamin B₁₂ Deficiency [see *Warnings and Precautions (5.2)*]
- Hypoglycemia [see *Warnings and Precautions (5.3)*]

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In placebo-controlled trials, 781 patients were administered metformin hydrochloride extended-release tablets. Adverse reactions reported in greater than 5% of the patients treated with metformin hydrochloride extended-release tablets and that were more common than in placebo-treated patients are listed in Table 1.

Table 1: Adverse Reactions from Clinical Trials of Metformin Hydrochloride Extended-Release Tablets Occurring >5% and More Common than Placebo in Patients with Type 2 Diabetes Mellitus

Adverse Reaction	Metformin Hydrochloride Extended-Release Tablets (n=781)	Placebo (n=195)
Diarrhea	10%	3%
Nausea/Vomiting	7%	2%

Diarrhea led to the discontinuation of metformin hydrochloride extended-release tablets in 0.6% of patients. Additionally, the following adverse reactions were reported in 1.0% to 5.0% of patients treated with metformin hydrochloride extended-release tablets and were more commonly reported than in placebo-treated patients: abdominal pain, constipation, abdomen distention, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance.

Laboratory Tests

Vitamin B₁₂ Concentrations

In clinical trials of 29-week duration with metformin hydrochloride tablets, a decrease to subnormal levels of previously normal serum vitamin B₁₂ levels was observed in approximately 7% of patients.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of metformin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.

7 DRUG INTERACTIONS

Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.

Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets

Carbonic Anhydrase Inhibitors	
<i>Clinical Impact:</i>	Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.
<i>Intervention:</i>	Consider more frequent monitoring of these patients.
<i>Examples:</i>	Topiramate, zonisamide, acetazolamide or dichlorphenamide.
Drugs that Reduce Metformin Hydrochloride Extended-Release Tablets Clearance	

<i>Clinical Impact:</i>	Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see <i>Clinical Pharmacology (12.3)</i>].
<i>Intervention:</i>	Consider the benefits and risks of concomitant use with metformin hydrochloride extended-release tablets.
<i>Examples:</i>	Ranolazine, vandetanib, dolutegravir, and cimetidine.
Alcohol	
<i>Clinical Impact:</i>	Alcohol is known to potentiate the effect of metformin on lactate metabolism.
<i>Intervention:</i>	Warn patients against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets.
Insulin Secretagogues or Insulin	
<i>Clinical Impact:</i>	Coadministration of metformin hydrochloride extended-release tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia.
<i>Intervention:</i>	Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin.
Drugs Affecting Glycemic Control	
<i>Clinical Impact:</i>	Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control.
<i>Intervention:</i>	When such drugs are administered to a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for hypoglycemia.
<i>Examples:</i>	Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or

miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see *Data*]. There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [see *Clinical Considerations*].

No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2- and 5- times, respectively, a 2550 mg clinical dose, based on body surface area [see *Data*].

The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes mellitus with an HbA1C >7 and has been reported to be as high as 20 to 25% in women with a HbA1C >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Data

Human Data

Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups.

Animal Data

Metformin hydrochloride did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 5 times a 2550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

8.2 Lactation

Risk Summary

Limited published studies report that metformin is present in human milk [see *Data*]. However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metformin hydrochloride extended-release tablets and any potential adverse effects on the breastfed child from metformin hydrochloride extended-release tablets or from the underlying maternal condition.

Data

Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.

8.3 Females and Males of Reproductive Potential

Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin hydrochloride extended-release tablets may result in ovulation in some anovulatory women.

8.4 Pediatric Use

Safety and effectiveness of metformin hydrochloride extended-release tablets in pediatric patients have not been established.

8.5 Geriatric Use

Controlled clinical studies of metformin hydrochloride extended-release tablets did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients [see *Warnings and Precautions (5.1)*].

8.6 Renal Impairment

Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Metformin hydrochloride extended-release tablets are contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² [see *Dosage and Administration (2.2)*, *Contraindications (4)*, *Warnings and Precautions (5.1)*, and *Clinical Pharmacology (12.3)*].

8.7 Hepatic Impairment


Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Metformin hydrochloride extended-release tablets are not recommended in patients with hepatic impairment [see *Warnings and Precautions (5.1)*].

10 OVERDOSAGE

Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see *Warnings and Precautions (5.1)*]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.

11 DESCRIPTION

Metformin hydrochloride extended-release tablets USP contain the biguanidine antihyperglycemic agent, metformin, in the form of monohydrochloride salt. The chemical name of metformin hydrochloride is N, N-dimethylimidodicarbonimidic diamide hydrochloride with a molecular formula of $C_4H_{11}N_5 \cdot HCl$ and a molecular weight of 165.63. Its structural formula is:



Metformin hydrochloride USP is a white crystalline powder that is freely soluble in water and is practically insoluble in acetone, ether and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.

Metformin hydrochloride extended-release tablets USP deliver 500 mg or 1,000 mg of metformin hydrochloride USP, which is equivalent to 389.93 mg or 779.86 mg metformin, respectively. In addition to the active ingredient metformin hydrochloride USP, each tablet contains the following inactive ingredients: ammonio methacrylate copolymer type A, ammonio methacrylate copolymer type B, ammonium hydroxide, hydroxy propylcellulose, hypromellose, iron oxide black, magnesium stearate, microcrystalline cellulose, polysorbate 80, propylene glycol, shellac, talc and triethyl citrate.

FDA approved dissolution test differs from the USP monograph.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.

12.3 Pharmacokinetics

Absorption

In a multiple-dose crossover study, 23 patients with type 2 diabetes mellitus were administered either metformin hydrochloride extended-release tablets 2,000 mg once a day (after dinner) or metformin hydrochloride tablets 1,000 mg twice a day (after breakfast and after dinner). After 4 weeks of treatment, steady-state pharmacokinetic parameters, area under the concentration-time curve (AUC), time to peak plasma concentration (T_{max}), and maximum concentration (C_{max}) were evaluated. The appearance of metformin in plasma from metformin hydrochloride extended-release tablets are slower and more prolonged compared to metformin hydrochloride tablets. Results are presented in **Table 3**.

Table 3 Metformin Hydrochloride Extended-Release Tablets vs. Metformin Hydrochloride Tablets Steady-State Pharmacokinetic Parameters at 4 Weeks		
Pharmacokinetic Parameters (mean ± SD)	Metformin Hydrochloride Extended-Release Tablets 2,000 mg (administered q.d. after dinner)	Metformin Hydrochloride Tablets* 2,000 mg (1,000 mg b.i.d.)
AUC _{0-24hr} (ng•hr/mL)	26,811 ± 7055	27,371 ± 5,781
T_{max} (hr)	6 (3 to 10)	3 (1 to 8)
C_{max} (ng/mL)	2849 ± 797	1820 ± 370

*Immediate-release metformin hydrochloride tablets

In four single-dose studies and one multiple-dose study, the bioavailability of metformin hydrochloride extended-release tablets 2,000 mg given once daily, in the evening, under fed conditions [as measured by AUC] was similar to the same total daily dose administered as metformin hydrochloride tablets 1,000 mg given twice daily. The geometric mean ratios (metformin hydrochloride extended-release tablets/metformin hydrochloride tablets) of AUC_{0-24hr}, AUC_{0-72hr}, and AUC_{0-inf} for these five studies ranged from 0.96 to 1.08.

In a single-dose, four-period replicate crossover design study, comparing two 500 mg metformin hydrochloride extended-release tablets to one 1,000 mg metformin hydrochloride extended-release tablet administered in the evening with food to 29 healthy male subjects, two 500 mg metformin hydrochloride extended-release tablets

were found to be equivalent to one 1,000 mg metformin hydrochloride extended-release tablet.

In a study carried out with metformin hydrochloride extended-release tablets, there was a dose-associated increase in metformin exposure over 24 hours following oral administration of 1,000, 1,500, 2,000, and 2,500 mg.

In three studies with metformin hydrochloride extended-release tablets using different treatment regimens (2,000 mg after dinner; 1,000 mg after breakfast and after dinner; and 2,500 mg after dinner), the pharmacokinetics of metformin as measured by AUC appeared linear following multiple-dose administration.

Effect of food: The extent of metformin absorption (as measured by AUC) from metformin hydrochloride extended-release tablets increased by approximately 60% when given with food. When metformin hydrochloride extended-release tablets was administered with food, C_{\max} was increased by approximately 30% and T_{\max} was more prolonged compared with the fasting state (6.1 versus 4.0 hours).

Distribution

The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride tablets 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time.

Metabolism

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.

Elimination

Renal clearance (see Table 4) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Specific Populations

Renal Impairment

In patients with decreased renal function the plasma and blood half-life of metformin is

prolonged and the renal clearance is decreased (see Table 4) [See *Dosage and Administration (2.2), Contraindications (4), and Warnings and Precautions (5.1) and Use in Specific Populations (8.6)*].

Hepatic Impairment

No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment [See *Warnings and Precautions (5.1) and Use in Specific Populations (8.7)*].

Geriatrics

Limited data from controlled pharmacokinetic studies of metformin hydrochloride tablets in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C_{max} is increased, compared to healthy young subjects. It appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 4). [See *Warnings and Precautions (5.1) and Use in Specific Populations (8.5)*].

Table 4: Select Mean (\pm S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin Hydrochloride Tablets

Subject Groups: Metformin Hydrochloride dose^a (number of subjects)	C_{max}^b (mcg/mL)	T_{max}^c (hrs)	Renal Clearance (mL/min)
Healthy, nondiabetic adults: 500 mg single dose (24) 850 mg single dose (74) ^d 850 mg three times daily for 19 doses ^e (9)	1.03 (\pm 0.33) 1.60 (\pm 0.38) 2.01 (\pm 0.42)	2.75 (\pm 0.81) 2.64 (\pm 0.82) 1.79 (\pm 0.94)	600 (\pm 132) 552 (\pm 139) 642 (\pm 173)
Adults with type 2 diabetes mellitus: 850 mg single dose (23) 850 mg three times daily for 19 doses ^e (9)	1.48 (\pm 0.5) 1.90 (\pm 0.62)	3.32 (\pm 1.08) 2.01 (\pm 1.22)	491 (\pm 138) 550 (\pm 160)
Elderly^f, healthy nondiabetic adults: 850 mg single dose (12)	2.45 (\pm 0.70)	2.71 (\pm 1.05)	412 (\pm 98)
Renal-impaired adults: 850 mg single dose			
Mild (CLcr ^g 61 to 90 mL/min) (5)	1.86 (\pm 0.52)	3.20 (\pm 0.45)	384 (\pm 122)
Moderate (CLcr 31 to 60 mL/min) (4)	4.12 (\pm 1.83)	3.75 (\pm 0.50)	108 (\pm 57)
Severe (CLcr 10 to 30 mL/min) (6)	3.93 (\pm 0.92)	4.01 (\pm 1.10)	130 (\pm 90)

^a All doses given fasting except the first 18 doses of the multiple dose studies

^b Peak plasma concentration

^c Time to peak plasma concentration

^d Combined results (average means) of five studies: mean age 32 years (range 23 to 59 years)

^e Kinetic study done following dose 19, given fasting

^f Elderly subjects, mean age 71 years (range 65 to 81 years)

^g CL_{cr} = creatinine clearance normalized to body surface area of 1.73 m²

Pediatrics

There are no available pharmacokinetic data with metformin hydrochloride extended-release tablets in pediatric patients.

Gender

Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes mellitus when analyzed according to gender (males=19, females=16).

Race

No studies of metformin pharmacokinetic parameters according to race have been performed.

Drug Interactions

In Vivo Assessment of Drug Interactions

Table 5: Effect of Coadministered Drug on Plasma Metformin Systemic Exposure

Coadministered Drug	Dose of Coadministered Drug*	Dose of Metformin Hydrochloride*	Geometric Mean Ratio (ratio with/without coadministered drug)		
			No Effect = 1.00		
			AUC[†]	C_{max}	
No dosing adjustments required for the following:					
Glyburide	5 mg	850 mg	metformin	0.91 [‡]	0.93 [‡]
Furosemide	40 mg	850 mg	metformin	1.09 [‡]	1.22 [‡]
Nifedipine	10 mg	850 mg	metformin	1.16	1.21
Propranolol	40 mg	850 mg	metformin	0.90	0.94
Ibuprofen	400 mg	850 mg	metformin	1.05 [‡]	1.07 [‡]
Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination [See Warnings and Precautions (5.1) and Drug Interactions (7).]					
Cimetidine	400 mg	850 mg	metformin	1.40	1.61

Carbonic anhydrase inhibitors may cause metabolic acidosis [See Warnings and Precautions (5.1) and Drug Interactions (7).]

Topiramate	100 mg [§]	500 mg [§]	metformin	1.25 [§]	1.17
------------	---------------------	---------------------	-----------	-------------------	------

*All metformin hydrochloride and coadministered drugs were given as single doses

† AUC = AUC_{inf}

‡ Ratio of arithmetic means

§ At steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC_{0-12h}

Table 6: Effect of Metformin on Coadministered Drug Systemic Exposure

Coadministered Drug	Dose of Coadministered Drug*	Dose of Metformin Hydrochloride*	Geometric Mean Ratio (ratio with/without metformin) No Effect = 1.00		
				AUC [†]	C _{max}
No dosing adjustments required for the following:					
Glyburide	5 mg	850 mg	glyburide	0.78 [‡]	0.63 [‡]
Furosemide	40 mg	850 mg	furosemide	0.87 [‡]	0.69 [‡]
Nifedipine	10 mg	850 mg	nifedipine	1.10 [§]	1.08
Propranolol	40 mg	850 mg	propranolol	1.01 [§]	1.02
Ibuprofen	400 mg	850 mg	ibuprofen	0.97 [¶]	1.01 [¶]
Cimetidine	400 mg	850 mg	cimetidine	0.95 [§]	1.01

*All metformin hydrochloride and coadministered drugs were given as single doses

† AUC = AUC_{inf} unless otherwise noted

‡ Ratio of arithmetic means, p-value of difference <0.05

§ AUC_{0-24 hr} reported

¶ Ratio of arithmetic means

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1,500 mg/kg/day, respectively. These doses are both approximately 3 times the maximum recommended human daily dose of 2550 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.

There was no evidence of a mutagenic potential of metformin in the following *in vitro*

tests: Ames test (*S. typhimurium*), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the *in vivo* mouse micronucleus test were also negative.

Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 2 times the maximum recommended human daily dose of 2550 mg based on body surface area comparisons.

14 CLINICAL STUDIES

A 24-week, double-blind, placebo-controlled study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal, was conducted in patients with type 2 diabetes mellitus who had failed to achieve glycemic control with diet and exercise. Patients entering the study had a mean baseline HbA_{1c} of 8.0% and a mean baseline FPG of 176 mg/dL. The treatment dose was increased to 1,500 mg once daily if at Week 12 HbA_{1c} was $\geq 7.0\%$ but $< 8.0\%$ (patients with HbA_{1c} $\geq 8.0\%$ were discontinued from the study). At the final visit (24-week), mean HbA_{1c} had increased 0.2% from baseline in placebo patients and decreased 0.6% with metformin hydrochloride extended-release tablets.

A 16-week, double-blind, placebo-controlled, dose-response study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal or twice daily with meals, was conducted in patients with type 2 diabetes mellitus who had failed to achieve glycemic control with diet and exercise. The results are shown in Table 7.

Table 7: Mean Changes from Baseline* in HbA_{1c} and Fasting Plasma Glucose at Week 16 Comparing Metformin Hydrochloride Extended-Release Tablets vs Placebo in Patients with Type 2 Diabetes Mellitus

	Metformin Hydrochloride Extended-Release Tablets					Placebo
	500 mg Once Daily	1,000 mg Once Daily	1,500 mg Once Daily	2,000 mg Once Daily	1,000 mg Twice Daily	
Hemoglobin A_{1c} (%)	(n=115)	(n=115)	(n=111)	(n=125)	(n=112)	(n=111)
Baseline	8.2	8.4	8.3	8.4	8.4	8.4
Change at FINAL VISIT	-0.4	-0.6	-0.9	-0.8	-1.1	0.1
p-value ^a	<0.001	<0.001	<0.001	<0.001	<0.001	-
FPG (mg/dL)	(n=126)	(n=118)	(n=120)	(n=132)	(n=122)	(n=113)
Baseline	182.7	183.7	178.9	181.0	181.6	179.6
Change at FINAL VISIT	-15.2	-19.3	-28.5	-29.9	-33.6	7.6
p-value ^a	<0.001	<0.001	<0.001	<0.001	<0.001	-

^a All comparisons versus Placebo

Mean baseline body weight was 193 lbs, 192 lbs, 188 lbs, 196 lbs, 193 lbs and 194 lbs in

the metformin hydrochloride extended- release tablets 500 mg, 1,000 mg, 1,500 mg, and 2,000 mg once daily, 1,000 mg twice daily and placebo arms, respectively. Mean change in body weight from baseline to week 16 was -1.3 lbs, -1.3 lbs, -0.7 lbs, -1.5 lbs, -2.2 lbs and -1.8 lbs, respectively.

A 24-week, double-blind, randomized study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal, and metformin hydrochloride tablets, taken twice daily (with breakfast and evening meal), was conducted in patients with type 2 diabetes mellitus who had been treated with metformin hydrochloride tablets 500 mg twice daily for at least 8 weeks prior to study entry. The results are shown in Table 8.

Table 8: Mean Changes from Baseline* in HbA1c and Fasting Plasma Glucose at Week 24 Comparing Metformin Hydrochloride Extended-Release vs Metformin Hydrochloride in Patients with Type 2 Diabetes Mellitus

	Metformin Hydrochloride 500 mg Twice Daily (n=67)	Metformin Hydrochloride Extended-Release	
		1,000 mg Once Daily (n=72)	1,500 mg Once Daily (n=66)
Hemoglobin A1c (%)			
Baseline	7.06	6.99	7.02
Change at FINAL VISIT (95% CI)	0.14 ^a (-0.04, 0.31)	0.27 (0.11, 0.43)	0.13 (-0.02, 0.28)
FPG (mg/dL)			
Baseline	127.2	131.0	131.4
Change at FINAL VISIT (95% CI)	14.0 (7.0, 21.0)	11.5 (4.4, 18.6)	7.6 (1.0, 14.2)

^an=68

Mean baseline body weight was 210 lbs, 203 lbs and 193 lbs in the metformin hydrochloride tablets 500 mg twice daily, and metformin hydrochloride extended-release tablets 1,000 mg and 1,500 mg once daily arms, respectively. Mean change in body weight from baseline to week 24 was 0.9 lbs, 1.1 lbs and 0.9 lbs, respectively.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Metformin Hydrochloride Extended-Release Tablets USP are supplied as follows:

Metformin Hydrochloride Extended-Release Tablets USP 500 mg are white to off-white round biconvex tablets imprinted with 'MTN 500' on one side with black ink.

Bottles of 60

NDC 59651-042-60

Metformin Hydrochloride Extended-Release Tablets USP 1000 mg are white to off-white round biconvex tablets imprinted with 'MTN 1000' on one side with black ink.

Bottles of 60

NDC 59651-043-60

16.2 Storage

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat and humidity.

Keep tightly closed (protect from moisture). Protect from light.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Lactic Acidosis:

Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue metformin hydrochloride extended-release tablets immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving metformin hydrochloride extended-release tablets. Instruct patients to inform their doctor that they are taking metformin hydrochloride extended-release tablets prior to any surgical or radiological procedure, as temporary discontinuation may be required [see *Warnings and Precautions (5.1)*].

Hypoglycemia:

Inform patients that hypoglycemia may occur when metformin hydrochloride extended-release tablets are coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development [see *Warnings and Precautions (5.3)*].

Vitamin B₁₂ Deficiency:

Inform patients about importance of regular hematological parameters while receiving metformin hydrochloride extended-release tablets [see *Warnings and Precautions (5.2)*].

Females of Reproductive Age:

Inform females that treatment with metformin hydrochloride extended-release tablets

may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy [see *Use in Specific Populations (8.3)*].

Administration Information:

Inform patients that metformin hydrochloride extended-release tablets must be swallowed whole and not crushed, cut, or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.

Distributed by:

Aurobindo Pharma USA, Inc.
279 Princeton-Hightstown Road
East Windsor, NJ 08520

Manufactured by:

Aurobindo Pharma Limited
Hyderabad-500 032, India

Revised: 04/2026

PATIENT INFORMATION

Metformin Hydrochloride (met for' min hye'' droe klor' ide) Extended-Release Tablets, USP

What is the most important information I should know about metformin hydrochloride extended-release tablets?

Metformin hydrochloride extended-release tablets can cause serious side effects including:

Lactic Acidosis. Metformin hydrochloride, the medicine in metformin hydrochloride extended-release tablets, can cause a rare, but serious side effect called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in a hospital.

Stop taking metformin hydrochloride extended-release tablets and call your healthcare provider right away if you get any of the following symptoms of lactic acidosis:

- feel very weak and tired
- have unusual (not normal) muscle pain
- have trouble breathing
- have unexplained stomach or intestinal problems with nausea and vomiting, or diarrhea
- have unusual sleepiness or sleep longer than usual
- feel cold, especially in your arms and legs

- feel dizzy or lightheaded
- have a slow or irregular heartbeat

You have a higher chance of getting lactic acidosis if you:

- have severe kidney problems. See **“Do not take metformin hydrochloride extended-release tablets if you:”**
- have liver problems.
- have congestive heart failure that requires treatment with medicines.
- drink a lot of alcohol (very often or short-term “binge” drinking).
- get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity or exercise and do not drink enough fluids.
- have certain x-ray tests with injectable dyes or contrast agents.
- have surgery.
- have a heart attack, severe infection, or stroke.
- are 65 years of age or older.
- have a genetically inherited disease affecting mitochondria (the energy-producing parts within cells).

Tell your healthcare provider if you have any of the problems in the list above.

Tell your healthcare provider that you are taking metformin hydrochloride extended-release tablets before you have surgery or x-ray tests. Your healthcare provider may need to stop metformin hydrochloride extended-release tablets for a while if you have surgery or certain x-ray tests).

Metformin hydrochloride extended-release tablets can have other serious side effects. See **“What are the possible side effects of metformin hydrochloride extended-release tablets?”**

What are metformin hydrochloride extended-release tablets?

- Metformin hydrochloride extended-release tablets are prescription medicine that contains metformin hydrochloride. Metformin hydrochloride extended-release tablets are used with diet and exercise to help control high blood sugar (hyperglycemia) in adults with type 2 diabetes.
- It is not known if metformin hydrochloride extended-release tablets are safe and effective in children under 18 years of age.

Do not take metformin hydrochloride extended-release tablets if you:

- have severe kidney problems
- are allergic to metformin hydrochloride or any of the ingredients in metformin hydrochloride extended-release tablets. See the end of this Patient Information leaflet for a complete list of ingredients in metformin hydrochloride extended-release tablets.
- have a condition called metabolic acidosis including diabetic ketoacidosis (high levels of certain acids called “ketones” in your blood or urine).

Before taking metformin hydrochloride extended-release tablets, tell your healthcare provider about all your medical conditions, including if you:

- have a history or risk for diabetic ketoacidosis. See **“Do not take metformin hydrochloride extended-release tablets if you:”**
- have kidney problems.
- have liver problems.
- have heart problems, including congestive heart failure.
- are 65 years of age or older.
- drink alcohol very often or drink a lot of alcohol in short-term “binge” drinking.
- have a genetically inherited disease affecting mitochondria (the energy-producing parts within cells).
- are taking insulin or a sulfonylurea medicine.
- are pregnant or plan to become pregnant. It is not known if metformin hydrochloride extended-release tablets will harm your unborn baby. If you are pregnant, talk with your healthcare provider about the best way to control your blood sugar while you are pregnant.
- are a woman who has not gone through menopause (premenopausal) who does not have periods regularly or at all. Metformin hydrochloride extended-release tablets can cause the release of an egg from an ovary in a woman (ovulation). This can increase your chance of getting pregnant.
- are breastfeeding or plan to breastfeed. Metformin hydrochloride can pass into your breast milk. Talk with your healthcare provider about the best way to feed your baby while you take metformin hydrochloride extended-release tablets.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Metformin hydrochloride extended-release tablets may affect the way other medicines work, and other medicines may affect how metformin hydrochloride extended-release tablet works.

How should I take metformin hydrochloride extended-release tablets?

- Take metformin hydrochloride extended-release tablets exactly as your healthcare provider tells you.
- Metformin hydrochloride extended-release tablets should be taken with your evening meals to help decrease an upset stomach.
- Swallow metformin hydrochloride extended-release tablet whole. Do not crush, cut, or chew the tablets.
- You may sometimes pass a soft mass in your stools (bowel movement) that looks like metformin hydrochloride extended-release tablet. This is not harmful and will not affect the way metformin hydrochloride extended-release tablet works.
- When your body is under some types of stress, such as fever, trauma (such as a car accident), infection, or surgery, the amount of diabetes medicine that you need may change. Tell your healthcare provider right away if you have any of these

problems.

- Your healthcare provider should do blood tests to check how well your kidneys are working before and during your treatment with metformin hydrochloride extended-release tablets.
- Your healthcare provider will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.
- Low blood sugar (hypoglycemia) can happen more often when metformin hydrochloride extended-release tablets are taken with certain other diabetes medicines.

Talk to your healthcare provider about how to prevent, recognize and manage low blood sugar. See **“What are the possible side effects of metformin hydrochloride extended-release tablets?”**

- Check your blood sugar as your healthcare provider tells you to.
- Stay on your prescribed diet and exercise program while taking metformin hydrochloride extended-release tablets.
- If you take too much metformin hydrochloride, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking metformin hydrochloride extended-release tablets?

Do not drink a lot of alcoholic drinks while taking metformin hydrochloride extended-release tablets. This means you should not binge drink for short periods, and you should not drink a lot of alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis.

What are the possible side effects of metformin hydrochloride extended-release tablets?

Metformin hydrochloride extended-release tablets may cause serious side effects, including:

- See **“What is the most important information I should know about metformin hydrochloride extended-release tablets?”**
- **Low vitamin B₁₂ (vitamin B₁₂ deficiency).** Using metformin hydrochloride extended-release tablets may cause a decrease in the amount of vitamin B₁₂ in your blood, especially if you have had low vitamin B₁₂ levels before. Your healthcare provider may do blood tests to check your vitamin B₁₂ levels.
- **Low blood sugar (hypoglycemia).** If you take metformin hydrochloride extended-release tablets with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take metformin hydrochloride extended-release tablets. Signs and symptoms of low blood sugar may include:
 - headache
 - drowsiness
 - weakness
 - irritability
 - hunger

- fast heartbeat
- confusion
- shaking or feeling jittery
- dizziness
- sweating

Common side effects of metformin hydrochloride extended-release tablets include:

- diarrhea
- nausea and vomiting
- gassiness (flatulence)
- indigestion
- stomach-area (abdominal) pain and swelling
- headache
- taste disturbance (unpleasant metallic taste)

These are not all the possible side effects of metformin hydrochloride extended-release tablets.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store metformin hydrochloride extended-release tablets?

Store metformin hydrochloride extended-release tablets at room temperature between 68°F to 77°F (20°C to 25°C). See insert.

Keep bottle tightly closed between each use to protect the metformin hydrochloride extended-release tablets from moisture.

Protect from light.

Keep metformin hydrochloride extended-release tablets and all medicines out of the reach of children.

General information about the safe and effective use of metformin hydrochloride extended-release tablets

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use metformin hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not give metformin hydrochloride extended-release tablets to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about metformin hydrochloride extended-release tablets that is written for health professionals.

What are the ingredients in metformin hydrochloride extended-release

tablets?

Active ingredients: metformin hydrochloride.

Inactive ingredients: Ammonio methacrylate copolymer type A, ammonio methacrylate copolymer type B, ammonium hydroxide, hydroxy propylcellulose, hypromellose, iron oxide black, magnesium stearate, microcrystalline cellulose, polysorbate 80, propylene glycol, shellac, talc and triethyl citrate.

For more information call Aurobindo Pharma USA, Inc. at 1-866-850-2876.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Distributed by:

Aurobindo Pharma USA, Inc.
279 Princeton-Hightstown Road
East Windsor, NJ 08520

Manufactured by:

Aurobindo Pharma Limited
Hyderabad-500 032, India

Revised: 04/2026

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (60 Tablets Bottle)

NDC 59651-042-60

Rx only
Metformin Hydrochloride
Extended-Release
Tablets USP
500 mg

AUROBINDO

60 Tablets

NDC 59651-042-60

Each extended-release tablet contains:
metformin hydrochloride USP 500 mg.

Distributed by:
Aurobindo Pharma USA, Inc.
279 Princeton-Hightstown Road
East Windsor, NJ 08520



Rx only

**Metformin Hydrochloride
Extended-Release
Tablets USP**

500 mg

AUROBINDO

60 Tablets

USUAL DOSAGE: See package insert for complete prescribing information.

WARNING: KEEP OUT OF THE REACH OF CHILDREN.

PHARMACIST: Dispense in tight, light-resistant container as defined in USP. Extended-release tablets should not be broken, crushed, or chewed.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat and humidity.

Made in India

Code: TS/DRUGS/22/2009

P 1 4 1 8 5 4 4



* Over Printing Zone

↓
45 x 15 mm
(dotted line not for printing)

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1000 mg (60 Tablets Bottle)

NDC 59651-043-60

Rx only

**Metformin Hydrochloride
Extended-Release
Tablets USP**

1000 mg

AUROBINDO

60 Tablets

NDC 59651-043-60

Rx only

**Metformin Hydrochloride
Extended-Release
Tablets USP**

1000 mg



60 Tablets

Each extended-release tablet contains: metformin hydrochloride USP 1000 mg.

USUAL DOSAGE: See package insert for complete prescribing information.

WARNING: KEEP OUT OF THE REACH OF CHILDREN.


PHARMACIST: Dispense in tight, light-resistant container as defined in USP. Extended-release tablets should not be broken, crushed, or chewed.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat and humidity.

Distributed by:
Aurobindo Pharma USA, Inc.
279 Princeton-Hightstown Road
East Windsor, NJ 08520

Made in India

Code: TS/DRUGS/22/2009



P1418545



* Over Printing Zone

45 x 20 mm
(dotted line not for printing)

METFORMIN HYDROCHLORIDE

metformin hydrochloride tablet, extended release

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:59651-042
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
METFORMIN HYDROCHLORIDE (UNII: 786Z46389E) (METFORMIN - UNII:9100L32L2N)	METFORMIN HYDROCHLORIDE	500 mg

Inactive Ingredients

Ingredient Name	Strength
AMMONIO METHACRYLATE COPOLYMER TYPE A (UNII: 8GQS4E66YY)	
AMMONIO METHACRYLATE COPOLYMER TYPE B (UNII: 161H3B14U2)	
AMMONIA (UNII: 5138Q19F1X)	
HYDROXYPROPYL CELLULOSE (160000 WAMW) (UNII: 0A7M0N7SPE)	
HYPROMELLOSE 2208 (100000 MPA.S) (UNII: VM7F0B23ZI)	
FERROSO FERRIC OXIDE (UNII: XM0M87F357)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	

SHELLAC (UNII: 46N107B71O)				
TALC (UNII: 7SEV7J4R1U)				
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)				
Product Characteristics				
Color	WHITE (White to Off-white)	Score	no score	
Shape	ROUND (Biconvex)	Size	13mm	
Flavor		Imprint Code	MTN500	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:59651-042-60	60 in 1 BOTTLE; Type 0: Not a Combination Product	10/18/2024	
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA209694	10/18/2024		

METFORMIN HYDROCHLORIDE				
metformin hydrochloride tablet, extended release				
Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:59651-043	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
METFORMIN HYDROCHLORIDE (UNII: 786Z46389E) (METFORMIN - UNII:9100L32L2N)		METFORMIN HYDROCHLORIDE	1000 mg	
Inactive Ingredients				
Ingredient Name			Strength	
AMMONIO METHACRYLATE COPOLYMER TYPE A (UNII: 8GQS4E66YY)				
AMMONIO METHACRYLATE COPOLYMER TYPE B (UNII: 161H3B14U2)				
AMMONIA (UNII: 5138Q19F1X)				
HYDROXYPROPYL CELLULOSE (160000 WAMW) (UNII: 0A7M0N7SPE)				
HYPROMELLOSE 2208 (100000 MPA.S) (UNII: VM7F0B23ZI)				
FERROSO FERRIC OXIDE (UNII: XM0M87F357)				
MAGNESIUM STEARATE (UNII: 70097M6I30)				

MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
SHELLAC (UNII: 46N107B71O)	
TALC (UNII: 7SEV7J4R1U)	
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)	

Product Characteristics

Color	WHITE (White to Off-white)	Score	no score
Shape	ROUND (Biconvex)	Size	13mm
Flavor		Imprint Code	MTN1000
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:59651-043-60	60 in 1 BOTTLE; Type 0: Not a Combination Product	10/18/2024	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA209694	10/18/2024	

Labeler - Aurobindo Pharma Limited (650082092)

Establishment

Name	Address	ID/FEI	Business Operations
Aurobindo Pharma Limited		650381903	ANALYSIS(59651-042, 59651-043) , MANUFACTURE(59651-042, 59651-043)

Revised: 4/2026

Aurobindo Pharma Limited